UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: December 31,
2024
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ to ___________
Commission File Number: 001-39553

AMESITE INC.
(Exact name of registrant as specified in its charter)
Delaware | | 82-3431718 |
(State or other jurisdiction of
incorporation or organization) | | (I.R.S. Employer
Identification No.) |
| | |
607 Shelby Street
Suite 700 PMB 214
Detroit, MI | | 48226 |
(Address of principal executive offices) | | (Zip Code) |
(734) 876-8130
(Registrant’s telephone number, including
area code)
N/A
(Former name, former address and former fiscal
year, if changed since last report)
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Common Stock, par value $0.0001 | | AMST | | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes
☒ No ☐
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| | Emerging growth company | ☒ |
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐
No ☒
There were 3.994.107 shares of the registrant’s
common stock issued and outstanding as of February 5, 2025.
TABLE OF CONTENTS
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS
This
Quarterly Report on Form 10-Q contains “forward-looking statements” which include information relating to future events, future
financial performance, financial projections, strategies, expectations, competitive environment and regulation. Words such as “may,”
“should,” “could,” “would,” “predicts,” “potential,” “continue,”
“expects,” “anticipates,” “future,” “intends,” “plans,” “believes,”
“estimates,” and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking
statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance
or results will be achieved. Forward-looking statements are based on information we have when those statements are made or management’s
good faith belief as of that time with respect to future events, and are subject to a number of risks, and uncertainties and assumptions
that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.
These risks are more fully described in the “Risk Factors” section of this Quarterly Report on Form 10-Q. The following is
a summary of such risks:
|
● |
our healthcare app’s ability to enable our clients to offer AI-driven tools and resources to do their jobs more efficiently and effectively, without becoming software tech companies; |
|
|
|
|
● |
our healthcare app’s ability to result in opportunistic incremental revenue for our clients through use of AI-driven tools; |
|
|
|
|
● |
our ability to continue as a going concern; |
|
|
|
|
● |
our ability to obtain additional funds for our operations; |
|
|
|
|
● |
our ability to obtain and maintain intellectual property protection for our technologies and our ability to operate our business without infringing the intellectual property rights of others; |
|
|
|
|
● |
our reliance on third parties to conduct our business and studies; |
|
|
|
|
● |
our reliance on third party designers, suppliers, and partners to provide and maintain our platform; |
|
|
|
|
● |
our ability to attract and retain qualified key management and technical personnel; |
|
|
|
|
● |
our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act, or JOBS Act; |
|
|
|
|
● |
our financial performance; |
|
|
|
|
● |
the impact of government regulation and developments relating to our competitors or our industry; and |
|
|
|
|
● |
other risks and uncertainties, including those listed under the caption “Risk Factors.” |
These
statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties
and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance
or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from
current expectations include, among other things, those listed under the section titled “Item 1A. Risk Factors” and elsewhere
in our Annual Report on Form 10-K/A for the year ended June 30, 2024, filed with the Securities and Exchange Commission (“SEC”)
on January 2, 2025.
Any
forward-looking statements in this Quarterly Report on Form 10-Q reflect our current view with respect to future events and are subject
to these and other risks, uncertainties and assumptions relating to our business, results of operations, industry and future growth. Given
these uncertainties, you should not place undue reliance on these forward-looking statements. No forward-looking statement is a guarantee
of future performance. You should read this Quarterly Report on Form 10-Q, and the documents that we reference herein and have filed as
exhibits hereto completely and with the understanding that our actual future results may be materially different from any future results
expressed or implied by these forward-looking statements. Except as required by law, we assume no obligation to update or revise these
forward-looking statements for any reason, even if new information becomes available in the future.
This
Quarterly Report on Form 10-Q also contains, or may contain, estimates, projections and other information concerning our industry, our
business and the markets for our products, including data regarding the estimated size of those markets and their projected growth rates.
Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual
events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly
stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared
by third parties, industry and general publications, government data and similar sources. In some cases, we do not expressly refer to
the sources from which these data are derived.
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
Amesite
Inc.
Condensed Financial Statements
December 31, 2024
Amesite Inc.
Contents
Amesite, Inc.
Condensed Balance Sheets (unaudited)
| |
December 31, 2024 | | |
June 30, 2024 | |
Assets | |
| | |
| |
Current Assets | |
| | |
| |
Cash and cash equivalents | |
$ | 519,706 | | |
$ | 2,071,016 | |
Restricted cash | |
| 100,000 | | |
| 100,000 | |
Accounts receivable | |
| - | | |
| 30,060 | |
Prepaid expenses and other current assets | |
| 825,495 | | |
| 403,489 | |
Total current assets | |
| 1,445,201 | | |
| 2,604,565 | |
| |
| | | |
| | |
Noncurrent Assets | |
| | | |
| | |
Property and equipment - net | |
| 52,110 | | |
| 64,784 | |
Capitalized software - net | |
| 638,891 | | |
| 644,828 | |
Total noncurrent assets | |
| 691,001 | | |
| 709,612 | |
| |
| | | |
| | |
Total assets | |
$ | 2,136,202 | | |
$ | 3,314,177 | |
| |
| | | |
| | |
Liabilities and Stockholders’ Equity | |
| | | |
| | |
Current Liabilities | |
| | | |
| | |
Accounts payable | |
$ | 144,785 | | |
$ | 48,907 | |
Accrued and other current liabilities: | |
| | | |
| | |
Accrued compensation | |
| 685,365 | | |
| 655,275 | |
Deferred revenue | |
| 15,925 | | |
| - | |
Other accrued liabilities | |
| 42,662 | | |
| 94,283 | |
Total current liabilities | |
| 888,737 | | |
| 798,465 | |
| |
| | | |
| | |
Commitments and Contingencies | |
| | | |
| | |
| |
| | | |
| | |
Stockholders’ Equity | |
| | | |
| | |
Common stock, $.0001 par value; 100,000,000 shares authorized; 2,792,440 and 2,542,440 shares issued and outstanding at December 31, 2024 and June 30, 2024, respectively | |
| 280 | | |
| 255 | |
Preferred stock, $.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2024 and June 30, 2024 | |
| - | | |
| - | |
Additional paid-in capital | |
| 41,110,368 | | |
| 40,348,958 | |
Accumulated deficit | |
| (39,863,183 | ) | |
| (37,833,501 | ) |
Total stockholders’ equity | |
| 1,247,465 | | |
| 2,515,712 | |
| |
| | | |
| | |
Total liabilities and stockholders’ equity | |
$ | 2,136,202 | | |
$ | 3,314,177 | |
See accompanying Notes to Condensed Financial Statements.
Amesite, Inc.
Condensed Statements of Operations (unaudited)
| |
Three Months Ended | | |
Six Months Ended | |
| |
December 31, | | |
December 31, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
| |
| | |
| | |
| | |
| |
Net Revenue | |
$ | 12,760 | | |
$ | 41,443 | | |
$ | 24,010 | | |
$ | 104,776 | |
| |
| | | |
| | | |
| | | |
| | |
Operating Expenses | |
| | | |
| | | |
| | | |
| | |
General and administrative expenses | |
| 804,652 | | |
| 443,801 | | |
| 1,437,774 | | |
| 882,063 | |
Technology and content development | |
| 211,867 | | |
| 331,224 | | |
| 351,525 | | |
| 664,658 | |
Sales and marketing | |
| 127,110 | | |
| 222,502 | | |
| 292,924 | | |
| 464,129 | |
Total operating expenses | |
| 1,143,629 | | |
| 997,527 | | |
| 2,082,223 | | |
| 2,010,850 | |
| |
| | | |
| | | |
| | | |
| | |
Loss from Operations | |
| (1,130,869 | ) | |
| (956,084 | ) | |
| (2,058,213 | ) | |
| (1,906,074 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other Income | |
| | | |
| | | |
| | | |
| | |
Interest income | |
| 9,232 | | |
| 50,473 | | |
| 28,531 | | |
| 109,770 | |
Total other income | |
| 9,232 | | |
| 50,473 | | |
| 28,531 | | |
| 109,770 | |
| |
| | | |
| | | |
| | | |
| | |
Net Loss | |
$ | (1,121,637 | ) | |
$ | (905,611 | ) | |
$ | (2,029,682 | ) | |
$ | (1,796,304 | ) |
| |
| | | |
| | | |
| | | |
| | |
Earnings per Share | |
| | | |
| | | |
| | | |
| | |
Basic and diluted loss per share | |
$ | (0.40 | ) | |
$ | (0.36 | ) | |
$ | (0.73 | ) | |
$ | (0.71 | ) |
Weighted average shares outstanding | |
| 2,792,440 | | |
| 2,542,440 | | |
| 2,777,494 | | |
| 2,542,440 | |
See accompanying Notes to Condensed Financial Statements.
Amesite, Inc.
Condensed Statement Of Stockholders’ Equity
(unaudited)
| |
| | |
| | |
Additional | | |
| | |
| |
| |
Common Stock | | |
Paid-In | | |
Accumulated | | |
| |
| |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Total | |
Balance - July 1, 2023 | |
| 2,542,440 | | |
$ | 255 | | |
$ | 39,514,489 | | |
$ | (33,430,319 | ) | |
$ | 6,084,425 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| (890,693 | ) | |
| (890,693 | ) |
Stock-based compensation expense | |
| - | | |
| - | | |
| 55,098 | | |
| - | | |
| 55,098 | |
Balance - September 30, 2023 | |
| 2,542,440 | | |
| 255 | | |
| 39,569,587 | | |
| (34,321,012 | ) | |
| 5,248,830 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| (905,611 | ) | |
| (905,611 | ) |
Stock-based compensation expense | |
| - | | |
| - | | |
| 33,133 | | |
| - | | |
| 33,133 | |
Balance - December 31, 2023 | |
| 2,542,440 | | |
$ | 255 | | |
$ | 39,602,720 | | |
$ | (35,226,623 | ) | |
$ | 4,376,352 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance - July 1, 2024 | |
| 2,542,440 | | |
$ | 255 | | |
$ | 40,348,958 | | |
$ | (37,833,501 | ) | |
$ | 2,515,712 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| (908,045 | ) | |
| (908,045 | ) |
Issuance of common stock for consulting services | |
| 250,000 | | |
| 25 | | |
| 654,975 | | |
| - | | |
| 655,000 | |
Stock-based compensation expense | |
| - | | |
| - | | |
| 65,440 | | |
| - | | |
| 65,440 | |
Balance - September 30, 2024 | |
| 2,792,440 | | |
| 280 | | |
| 41,069,373 | | |
| (38,741,546 | ) | |
| 2,328,107 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| (1,121,637 | ) | |
| (1,121,637 | ) |
Stock-based compensation expense | |
| - | | |
| - | | |
| 40,995 | | |
| - | | |
| 40,995 | |
Balance - December 31, 2024 | |
| 2,792,440 | | |
$ | 280 | | |
$ | 41,110,368 | | |
$ | (39,863,183 | ) | |
$ | 1,247,465 | |
See accompanying Notes to Condensed Financial Statements.
Amesite, Inc.
Condensed Statements Of Cash Flows (unaudited)
| |
Six Months Ended | |
| |
December 31, | |
| |
2024 | | |
2023 | |
Cash Flows from Operating Activities | |
| | |
| |
Net Loss | |
$ | (2,029,682 | ) | |
$ | (1,796,304 | ) |
Adjustments to reconcile change in net loss to net cash used in operating activities: | |
| | | |
| | |
Depreciation and amortization | |
| 231,210 | | |
| 292,025 | |
Stock-based compensation expense | |
| 106,435 | | |
| 88,232 | |
Value of common stock issued in exchange for consulting services | |
| 655,000 | | |
| - | |
Changes in operating assets and liabilities which used cash: | |
| | | |
| | |
Accounts receivable | |
| 30,060 | | |
| 15,000 | |
Prepaid expenses and other current assets | |
| (422,006 | ) | |
| (87,421 | ) |
Accounts payable | |
| 95,878 | | |
| (5,244 | ) |
Accrued compensation | |
| 30,090 | | |
| (25,400 | ) |
Deferred revenue | |
| 15,925 | | |
| (40,833 | ) |
Accrued and other liabilities | |
| (51,621 | ) | |
| (17,887 | ) |
Net cash and cash equivalents used in operating activities | |
| (1,338,711 | ) | |
| (1,577,832 | ) |
Cash Flows from Investing Activities | |
| | | |
| | |
Purchase of property and equipment | |
| - | | |
| (1,166 | ) |
Investment in capitalized software | |
| (212,599 | ) | |
| (118,200 | ) |
Net cash and cash equivalents used in investing activities | |
| (212,599 | ) | |
| (119,366 | ) |
| |
| | | |
| | |
Net decrease in cash, cash equivalents, and restricted cash | |
| (1,551,310 | ) | |
| (1,697,198 | ) |
Cash, cash equivalents, and restricted cash - Beginning of period | |
| 2,171,016 | | |
| 5,360,661 | |
Cash, cash equivalents, and restricted cash - End of period | |
$ | 619,706 | | |
$ | 3,663,463 | |
| |
| | | |
| | |
SUPPLEMENTAL CASH FLOW INFORMATION: | |
| | | |
| | |
Cash paid for interest | |
$ | - | | |
$ | - | |
Cash paid for income taxes | |
$ | - | | |
$ | - | |
See accompanying Notes to Condensed Financial Statements.
Amesite, Inc.
Notes
to Condensed Financial Statements
Note 1 - Nature of Business
Amesite
Inc. (the “Company”) was incorporated in November 2017. Amesite is a pioneering technology company specializing in the development
and marketing of B2C and B2B AI-driven solutions, including its higher ed platform and healthcare app. Leveraging its proprietary AI infrastructure,
Amesite offers cutting-edge applications that cater to both individual and professional needs. NurseMagic™, the company’s
mobile healthcare app, streamlines creation of nursing notes and documentation tasks, enhances patient communication, and offers personalized
guidance to nurses on patient care, medications, and handling challenging workplace situations.
Note 2 - Significant Accounting
Policies
Basis
of Presentation
The condensed
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America (“GAAP”) and considering the requirements of the United States Securities and Exchange Commission (“SEC”).
The Company has a June 30 fiscal year.
In the opinion
of management, the condensed financial statements of the Company as of December 31, 2024 and June 30, 2024 and for the six months ended
December 31, 2024 and 2023 include all adjustments and accruals, consisting only of normal, recurring accrual adjustments, which are necessary
for a fair presentation of the results for the interim periods. These interim results are not necessarily indicative of results for a
full year.
Certain
information and footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed
in or omitted from this report pursuant to the rules and regulations of the SEC. These condensed financial statements should be read together
with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30,
2024.
The Company
has only one operating segment, as defined by Accounting Standards Codification (“ASC”) 280, “Segment Reporting.”
Going Concern
The accompanying condensed financial statements
have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates the realization
of assets and the satisfaction of liabilities in the normal course of business.
The Company is developing its customer base and
has not completed its efforts to establish a stabilized source of revenue sufficient to cover its expenses. The Company has had a history
of net losses and negative cash flows from operating activities since inception and expects to continue to incur net losses and use cash
in its operations in the foreseeable future.
The assessment of the Company’s ability
to meet its future obligations is inherently judgmental, subjective and susceptible to change. Based on their current forecast, management
believes that it may not have sufficient cash and cash equivalents to maintain the Company’s planned operations for the next twelve
months following the issuance of these condensed financial statements.
The Company has considered both quantitative and
qualitative factors that are known or reasonably known as of the date of these condensed financial statements are issued and concluded
that there are conditions present in the aggregate that raise substantial doubt about the Company’s ability to continue as a going
concern. In response to the conditions, management plans include generating cash by completing financing transactions, which may include
offerings of common stock. However, these plans are subject to market conditions, and are not within the Company’s control, and
therefore, cannot be deemed probable. There is no assurance that the Company will be successful in implementing their plans. As a result,
the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue
as a going concern. The condensed financial statements do not include any adjustments relating to the recoverability and classification
of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.
Use
of Estimates
The preparation
of condensed financial statements in conformity with generally accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities at the date of the condensed financial statements and the reported
amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Cash
and Cash Equivalents
The Company
considers all investments with an original maturity of three months or less when purchased to be cash equivalents. The total amount of
bank deposits (checking and savings accounts) insured by the FDIC at the period ended December 31, 2024 was $250,000.
As of June
30, 2024, the Company reclassified a portion of its cash balance to “Restricted Cash” in the balance sheets to reflect amounts
pledged as collateral for the Company’s credit card facility. As of December 31, 2024 and June 30, 2024, restricted cash totaled
$100,000.
The following
is a reconciliation of cash, cash equivalents, and restricted cash reported on the balance sheet and those reported on the statement of
cash flows for six months ended December 31, 2024 and 2023.
| |
December 31, | | |
December 31, | |
| |
2024 | | |
2023 | |
| |
| | |
| |
Cash and cash equivalents | |
$ | 519,706 | | |
$ | 3,663,463 | |
Restricted cash | |
| 100,000 | | |
| - | |
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows | |
$ | 619,706 | | |
$ | 3,663,463 | |
Prepaid
Expenses
The Company considers all items incurred for future
services to be prepaid expenses. At December 31, 2024 and June 30, 2024, the Company’s prepaid expenses consisted of the following.
| |
December 31, | | |
June 30, | |
| |
2024 | | |
2024 | |
| |
| | |
| |
Insurance | |
$ | 128,769 | | |
$ | 70,830 | |
Professional services | |
| 655,000 | | |
| - | |
Stock-based compensation | |
| - | | |
| 300,000 | |
Other general and administrative | |
| 41,726 | | |
| 32,659 | |
| |
$ | 825,495 | | |
$ | 403,489 | |
Property
and Equipment
Property
and equipment are recorded at cost. The straight-line method is used for computing depreciation and amortization. Assets are depreciated
over their estimated useful lives. The cost of leasehold improvements is depreciated (amortized) over the lesser of the length of the
related leases or the estimated useful lives of the assets. Costs of maintenance and repairs are charged to expense when incurred.
| | Depreciable Life - Years |
Leasehold improvements | | Shorter of estimated lease term or 10 years |
Furniture and fixtures | | 7 years |
Computer equipment and software | | 5 years |
Capitalized
Software Costs
The Company capitalizes costs incurred in the
development of software for its customers, including the costs of the software, materials, consultants, and payroll and payroll related
costs for employees incurred in developing computer software. Software development projects
generally include three stages: the preliminary project stage (all costs are expensed as incurred), the application development stage
(certain costs are capitalized and certain costs are expensed as incurred) and the post-implementation/operation stage (all costs are
expensed as incurred). Capitalization of costs requires judgment in determining when a project has reached the application development
stage, the proportion of time spent in the application development stage, and the period over which we expect to benefit from the use
of that software. Once the software is placed in service, these costs are amortized on the straight-line method over the estimated
useful life of the software, which is generally three years.
|
|
December 31, |
|
|
June 30, |
|
|
|
2024 |
|
|
2024 |
|
Beginning capitalized software |
|
$ |
3,993,691 |
|
|
$ |
3,618,991 |
|
Additions |
|
|
212,600 |
|
|
|
374,700 |
|
Ending capitalized software |
|
$ |
4,206,291 |
|
|
$ |
3,993,691 |
|
|
|
|
|
|
|
|
|
|
Beginning accumulated amortization |
|
$ |
3,348,863 |
|
|
$ |
2,840,545 |
|
Amortization expense |
|
|
218,537 |
|
|
|
508,318 |
|
Ending accumulated amortization |
|
$ |
3,567,400 |
|
|
$ |
3,348,863 |
|
|
|
|
|
|
|
|
|
|
Capitalized software - net |
|
$ |
638,891 |
|
|
$ |
644,828 |
|
Amortization
expense for the six months ended December 31, 2024 and 2023 was $218,537 and $279,351,
respectively and included as part of “Technology and content development” in the Statements of Operations.
Revenue
Recognition
We generate
our revenue from contractual arrangements with our clients to provide a comprehensive platform of integrated technology and technology
enabled services related to product offerings. During the six months ended December 31, 2024 and 2023, we recognized revenue from contracts
with customers of $24,010 and $105,000, respectively, related to services provided over time.
Performance
Obligations and Timing of Recognition
A performance
obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is
allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.
This performance
obligation is satisfied as the partners receive and consume benefits, which occur ratably over the contract term.
Occasionally,
we provide professional services, such as custom development, non-complex implementation activities, training, and other various professional
services. We evaluate these services to determine if they are distinct and separately identifiable in the context of the contract. In
our contracts with customers that contain multiple performance obligations as a result of this assessment, we allocate the transaction
price to each separate performance obligation on a relative standalone selling price basis. Standalone selling prices of our solutions
and services are typically estimated based on observable transactions when the solutions or services are sold on a standalone basis. When
standalone selling prices are not observable, we utilize a cost-plus margin approach to allocate the transaction price.
We also
receive fees that are fixed in nature, such as annual license and maintenance charges, in place of or in conjunction with variable consideration.
The fees are recognized ratably over the service period of the contract that the Company’s platform is made available to the customer
(i.e., the customer simultaneously receives and consumes the benefit of the software over the contract service period).
For the
six months ended December 31, 2024 and 2023, all revenue recognized has been recognized over the related contract periods. For the six
months ended December 31, 2024, one customer represents 94% of total revenue. For the six months ended December 31, 2023, two customers
represent 21% each, one represents 18%, and one represents 14% of total revenue.
Accounts
Receivable, Contract Assets, and Deferred Liabilities
Balance
sheet items related to contracts consist of accounts receivable (net), contract assets, and deferred liabilities on our condensed balance
sheets. Accounts receivable is stated at net realizable value, and we utilize the allowance method to provide for doubtful accounts based
on management’s evaluation of the collectability of the amounts due. Our estimates are reviewed and revised periodically based on
historical collection experience and a review of the current status of accounts receivable. Historically, actual write-offs for uncollectible
accounts have not significantly differed from prior estimates. There was no allowance for doubtful accounts on accounts receivable balances
as of December 31, 2024 or June 30, 2024.
We may recognize
revenue prior to billing a customer when we have satisfied or partially satisfied our performance obligations as billings to our customers
may not be made until after the service period has commenced. As of December 31, 2024 and June 30, 2024 we do not have any such contract
assets.
Deferred
liabilities as of each balance sheet date represent the excess of amounts billed or received as compared to amounts recognized in revenue
on our condensed statements of operations as of the end of the reporting period, and such amounts are reflected as a current liability
on our condensed balance sheets as deferred revenue. We generally receive payments prior to completion of the service period and our performance
obligations. These payments are recorded as deferred liability until the services are delivered or until our obligations are otherwise
met, at which time revenue is recognized.
Some contracts
also involve annual license fees, for which upfront amounts are received from customers. In these contracts, the license fees received
in advance of the platform’s launch are recorded as deferred liabilities.
The following
table provides information on the changes in the balance of deferred liabilities:
| |
December 31, | | |
June 30, | |
| |
2024 | | |
2024 | |
Opening balance | |
$ | 35,625 | | |
$ | 53,958 | |
Plus billings | |
| 3,360 | | |
| 112,923 | |
Less revenue recognized | |
| (23,060 | ) | |
| (166,881 | ) |
| |
$ | 15,925 | | |
$ | - | |
Revenue
recognized during the six months ended December 31, 2024 and 2023 that was included in the deferred revenue balance that existed in the
opening balance of each year was approximately $0 and $40,800, respectively.
The deferred
revenue balance as of December 31, 2024 is expected to be recognized over the next 12 months.
Stock-Based
Compensation
We have
issued four types of stock-based awards under our stock plans: stock options, restricted stock units, deferred stock units, and stock
warrants. All stock-based awards granted to employees, directors and independent contractors are measured at fair value at each grant
date. We rely on the Black-Scholes option pricing model for estimating the fair value of stock-based awards granted, and expected volatility
is based on the historical volatility of the Company’s stock prices. Stock options generally vest over two years from the grant
date and generally have ten-year contractual terms. Restricted stock units generally have a term of 12 months from the closing date of
the agreement. Stock warrants issued have a term of five years. Information about the assumptions used in the calculation of stock-based
compensation expense is set forth in Note 3 in the Notes to Condensed Financial Statements.
Technology
and Content Development
Technology
and content development expenditures consist primarily of personnel and personnel-related expense and contracted services associated with
the maintenance of our platform as well as hosting and licensing costs and are charged to expense as incurred. It also includes amortization
of capitalized software costs and research and development costs related to improving our platform and creating content that are charged
to expense as incurred.
Fair
Value Measurements
Accounting
standards require certain assets and liabilities be reported at fair value in the condensed financial statements and provide a framework
for establishing that fair value. The framework for determining fair value is based on a hierarchy that prioritizes the inputs and valuation
techniques used to measure fair value.
Fair values
determined by Level 1 inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability
to access.
Fair values
determined by Level 2 inputs use other inputs that are observable, either directly or indirectly. These Level 2 inputs include quoted
prices for similar assets and liabilities in active markets and other inputs such as interest rates and yield curves that are observable
at commonly quoted intervals.
Level 3
inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the
related asset. These Level 3 fair value measurements are based primarily on management’s own estimates using pricing models, discounted
cash flow methodologies, or similar techniques.
In instances
wherein inputs used to measure fair value fall into different levels in the above fair value hierarchy, fair value measurements in their
entirety are categorized based on the lowest level input that is significant to the valuation. The Company’s assessment of the significance
of particular inputs to these fair value measurements requires judgment and considers factors specific to each asset or liability.
Income
Taxes
A current
tax liability or asset is recognized for the estimated taxes payable or refundable on tax returns for the year. Deferred tax liabilities
or assets are recognized for the estimated future tax effects of temporary differences between financial reporting and tax accounting.
Deferred
tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not
be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years
in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change
in tax rates is recognized in the statement of operations in the period that includes the enactment date.
Net
Loss per Share
At December
31, 2024 and June 30, 2024, the Company had 625,126 and 633,000 potentially dilutive shares of common stock related to common stock options
and warrants, respectively, as determined using the if-converted method. For the six months ended December 31, 2024 and 2023, the dilutive
effect of common stock options and common stock warrants has not been included in the average shares outstanding for the calculation of
net loss per share as the effect would be anti-dilutive as a result of our net losses in these periods.
Subsequent
Events
The Company
evaluated subsequent events through the date of this Form 10-Q and has determined that no events have occurred that would require recognition
or disclosure in the condensed financial statements except as follows.
On January
7, 2025, the Company entered into an underwriting agreement with Laidlaw & Company (UK) Ltd. (“Laidlaw”),
as representatives of several underwriters to issue and sell 1,201,667 shares of the Company’s common stock at a purchase price
of $3.00 per Share. As part of the offering, the Company agreed to issue the underwriters, or their designees, warrants to purchase
a number of shares of common stock equal to five percent (5%) of the number of shares sold to the public at an at an exercise price equal
to 125.0% of the offering price per share of Common Stock, or $3.75 per share. On January 8, 2025, the Company closed the offering, and
the Company sold 1,201,667 Shares to the underwriters for total gross proceeds of approximately $3.6 million. After deducting the underwriting
discounts, commission and expenses and estimated offering expenses payable by the Company, the Company received net proceeds of approximately
$3.08 million.
Risks
and Uncertainties
The Company
operates in an industry subject to rapid change. The Company’s operations will be subject to significant risk and uncertainties
including financial, operational, technological, and other risks associated with an early-stage company, including the potential risk
of business failure.
Recently
issued accounting standards
In November 2023, the Financial Accounting Standard
Board (the “FASB”) issued Accounting Standard Updates (“ASU”) No. 2023-07, “Segment Reporting (Topic 280):
Improvements to Reportable Segment Disclosures (“ASU 2023-07”),” which requires a public entity to disclose significant
segment expenses that are regularly provided to the chief operating decision maker (“CODM”), a description of other segment
items by reportable segment, and an explanation of any additional measures the CODM uses in deciding how to allocate resources, and extend
nearly all annual segment reporting requirements to quarterly reporting requirements. In addition, entities with a single reportable segment
must now provide all segment disclosures required in ASC 280, including the new disclosures for reportable segments under the amendments
in ASU 2023-07. The new guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years
beginning after December 15, 2024, and early adoption is permitted. The guidance will be applied on a retrospective basis, with such disclosures
to be made in regard to all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting
this ASU on its condensed consolidated financial statements and related disclosures.
In December 2023, the FASB issued ASU No. 2023-09,
“Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09),” which improves the transparency of
income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation
and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income
tax disclosures. This guidance will be effective for the annual periods beginning after December 31, 2024. Early adoption is permitted.
Upon adoption, the guidance can be applied prospectively or retrospectively. The Company is currently evaluating the guidance to determine
its impact on our condensed consolidated financial statements and related disclosures.
In November 2024, the FASB issued ASU No. 2024-03
“Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40)”
which requires disclosure each reporting period, in the notes to the financial statements, of specified information about certain costs
and expenses. For public business entities, the new requirements will be effective for annual periods beginning after December 15, 2026.
The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted.
The Company is currently evaluating the effect of adopting this ASU.
Note 3 - Stock-Based Compensation
The Company’s
Equity Incentive Plan (the “Plan”) permits the grant of stock options, stock appreciation rights, restricted stock, restricted
stock units, and deferred stock units to officers, employees, directors, consultants, agents, and independent contractors of the Company.
The Company believes that such awards align the interests of its employees, directors, and consultants with those of its stockholders.
Option awards
are generally granted with an exercise price equal to the market price of the Company’s stock at the date of grant; those option
awards generally vest over four years from the grant date and generally have ten-year contractual terms. Certain option awards provide
for accelerated vesting (as defined in the Plan).
The Company
estimates the fair value of each option award using a Black Scholes Model (“BSM”). Expected volatilities are based on historical
volatility of the Company’s stock. The Company uses historical data to estimate option exercise within the valuation model or estimates
the expected option exercise when historical data is unavailable. The risk-free rate for periods within the contractual life of the option
is based on the U.S. Treasury yield curve in effect at the time of grant. The Company has not paid any dividends on common stock since
its inception and does not anticipate paying dividends on its common stock in the foreseeable future. When calculating the amount of annual
compensation expense, the Company has elected not to estimate forfeitures and instead accounts for forfeitures as they occur.
500 and
0 options were granted for the six months ended December 31, 2024 or 2023, respectively. As of December 31, 2024, there were approximately
$31,000 of total unrecognized compensation costs for employees and non-employees related to nonvested options. These costs are expected
to be recognized through May 2027.
A summary
of options terminated, as well as those that vested, in the six months ended December 31, 2024 is presented below:
Options | | Number of Shares | | | Weighted Average Exercise Price | | | Weighted Average Remaining Contractual Term (in years) | |
Outstanding at July 1, 2024 | | | 235,219 | | | $ | 22.05 | | | | 5.6 | |
Terminated | | | - | | | | - | | | | - | |
Additional vesting | | | 5,909 | | | | 5.53 | | | | 8.3 | |
Outstanding and expected to vest at December 31, 2024 | | | 241,128 | | | $ | 20.76 | | | | 5.1 | |
On September 29, 2021, the board of directors
approved changes to our director compensation program for fiscal year 2022 and beyond. The board instituted an annual cash retainer for
directors in the amount of $48,000 per director with an additional retainer for the chair of our Compensation Committee and Audit
Committee of $7,500 and $10,000, respectively. Directors can choose to receive deferred stock units in lieu of cash payments. For
the six months ended December 31, 2024, $101,000 in deferred stock units were awarded and $35,765 in cash compensation was accrued.
On May 3,
2024, the board of directors of the Company approved an amendment to the Company’s 2018 Equity Incentive Plan (the “2018 Plan”)
to increase the number of shares available for issuance under the 2018 Plan by 508,488 shares and increase the number of shares
that may be issued pursuant to the exercise of incentive stock options by 508,488 shares. The amendment to the 2018 Plan is
intended to ensure that the Company can continue to provide an incentive to employees, directors and consultants by enabling them to share
in the Company’s future growth. The amendment to the 2018 Plan was approved by the Company’s stockholders at the Company’s
special meeting on June 18, 2024.
As of December 31, 2024, the Company has 615,643
shares of common stock available for granting under the Plan.
On July 11, 2024, the Company issued 250,000 shares
of common stock to a consultant under an agreement for activities related to potential future financing. The $655,000 market
value of those shares is reflected in the Company’s common stock and additional paid in capital accounts and has been capitalized
as deferred issuance costs in current assets until such time the financing is complete. These costs were recognized as an expense against
the proceeds of the public offering that closed January 8, 2025 pursuant to ASC 340-10-S99-1. See Note 2, Subsequent Events.
Note 4 - Warrants
The Company
measures the fair value of warrants using Black-Scholes Model. No warrants have been issued during the six months ended December 31, 2024
or 2023. As of December 31, 2024 and June 30, 2024, there were 383,998 and 397,781 warrants outstanding, respectively. The weighted average
exercise price is $11.88 with a weighted average remaining contractual term of 3 years at December 31, 2024.
Note
5 - Income Taxes
For the
six months ended December 31, 2024 and prior periods since inception, the Company’s activities have not generated taxable income
or tax liabilities. Accordingly, the Company has not recognized an income tax benefit on the Condensed Statements of Operations for the
six months ended December 31, 2024 and 2023.
The Company
has approximately $29.3 million of net operating loss carryforwards available to reduce future income taxes, of which approximately $17,000
of net operating loss carryforwards expire in 2037. Due to uncertainty as to the realization of the net operating loss carryforwards and
other deferred tax assets as a result of the Company’s limited operating history and operating losses since inception, a full valuation
allowance has been recorded against the Company’s deferred tax assets.
Note
6 - Revision to Prior Period Financial Statements
The stock
issued during the first fiscal quarter was valued at an incorrect date. This resulted in an overstatement of current assets and additional
paid-in capital at September 30, 2024. There was no impact on the statement of operations for the three months ended September 30, 2024.
The Company
evaluated the materiality of the error described above from a qualitative and quantitative perspective. Based on this evaluation, taking
into account the guidance in the SEC Staff Accounting Bulletin No. 99, “Materiality”, (“SAB 99”), the Company
concluded that the correction would not be material to the financial position or results of operations for the three ended September 30,
2024. The unaudited financial statements as of September 30, 2024, are revised as follows:
| |
As previously | | |
| | |
| |
| |
reported | | |
Revisions | | |
As revised | |
Balance sheet at September 30, 2024 | |
| | |
| | |
| |
Prepaid expenses and other current assets | |
$ | 962,021 | | |
$ | (65,000 | ) | |
$ | 897,021 | |
Total current assets | |
$ | 2,496,774 | | |
$ | (65,000 | ) | |
$ | 2,431,774 | |
Total assets | |
$ | 3,236,110 | | |
$ | (65,000 | ) | |
$ | 3,171,110 | |
| |
| | | |
| | | |
| | |
Additional paid-in capital | |
$ | 41,134,373 | | |
$ | (65,000 | ) | |
$ | 41,069,373 | |
Total stockholders’ equity | |
$ | 2,393,107 | | |
$ | (65,000 | ) | |
$ | 2,328,107 | |
Total liabilities and stockholders’ equity | |
$ | 3,236,110 | | |
$ | (65,000 | ) | |
$ | 3,171,110 | |
| |
| | | |
| | | |
| | |
Statement of Changes in Stockholders’ Equity for the three months ended September 30, 2024 | |
| | | |
| | | |
| | |
Revaluation of common shares issued for consulting services | |
$ | 720,000 | | |
$ | (65,000 | ) | |
$ | 655,000 | |
Additional paid-in capital | |
$ | 41,134,373 | | |
$ | (65,000 | ) | |
$ | 41,069,373 | |
Total stockholders’ equity | |
$ | 2,393,107 | | |
$ | (65,000 | ) | |
$ | 2,328,107 | |
| |
| | | |
| | | |
| | |
Statement of Cash Flows for the three months ended September 30, 2024 | |
| | | |
| | | |
| | |
Value of common stock issued in exchange for consulting services | |
$ | 720,000 | | |
$ | (65,000 | ) | |
$ | 655,000 | |
Prepaid expenses and other current assets | |
$ | (558,532 | ) | |
$ | 65,000 | | |
$ | (493,532 | ) |
Item 2. Management’s Discussion and Analysis
of Financial Condition and Results of Operations.
The following discussion and analysis of our
financial condition and results of operations should be read together with our unaudited condensed financial statements and related notes
appearing elsewhere in this Quarterly Report on Form 10-Q and our audited financial statements and related notes for the year ended June
30, 2024 included in our Annual Report on Form 10-K/A filed with the Securities and Exchange Commission, or SEC, on January 2, 2025. In
addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties,
and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain
factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this Quarterly Report
on Form 10-Q, including those factors set forth in the section entitled “Cautionary Statement Regarding Forward-Looking Statements”
and in the section entitled “Risk Factors” in Part II, Item 1A.
Overview
The following discussion highlights our results
of operations and the principal factors that have affected our financial condition as well as our liquidity and capital resources for
the six months ended December 31, 2024 and provides information that management believes is relevant for an assessment and understanding
of the statements of financial condition and results of operations presented herein. The following discussion and analysis are based on
our unaudited condensed financial statements contained in this Quarterly Report on Form 10-Q, which we have prepared in accordance with
United States generally accepted accounting principles, or GAAP, and the requirements of the SEC. You should read the discussion and analysis
together with such financial statements and the related notes thereto.
The Company is developing its customer base and
has not completed its efforts to establish a stabilized source of revenue sufficient to cover its expenses. The Company has had a history
of net losses and negative cash flows from operating activities since inception and expects to continue to incur net losses and use cash
in its operations in the foreseeable future.
We are not currently profitable, and we cannot
provide any assurance that we will ever be profitable. We incurred a net loss of $2,029,682 for the six months ended December 31, 2024,
and we incurred a net loss of $39.9 million for the period from November 14, 2017 (date of incorporation) to December 31, 2024.
The assessment of the
Company’s ability to meet its future obligations is inherently judgmental, subjective and susceptible to change. Based on their
current forecast, management believes that it will have sufficient cash and cash equivalents to maintain the Company’s planned operations
for the next twelve months following the issuance of these condensed financial statements; however, there is uncertainty in the forecast
and therefore the Company cannot assert that it is probable. The Company has considered both quantitative and qualitative factors that
are known or reasonably knowable as of the date of these condensed financial statements are issued and concluded that there are conditions
present in the aggregate that raise substantial doubt about the Company’s ability to continue as a going concern.
In response to the conditions,
management plans include generating cash by completing financing transactions, which may include offerings of common stock. However, these
plans are subject to market conditions, and are not within the Company’s control, and therefore, cannot be deemed probable. There
is no assurance that the Company will be successful in implementing their plans. As a result, the Company has concluded that management’s
plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.
Basis of Presentation
The financial statements contained herein have
been prepared in accordance with GAAP and the requirements of the SEC.
Financial Position, Liquidity, and Capital
Resources
We are not currently profitable, and we cannot
provide any assurance that we will ever be profitable. We incurred a net loss of $2,029,682 for the six months ended December 31, 2024,
and we incurred a net loss of $39.9 million for the period from November 14, 2017 (date of incorporation) to December 31, 2024.
During the period from November 14, 2017 (date
of incorporation) to September 30, 2020, we raised net proceeds of approximately $11,760,000 from private placement financing transactions
(stock and debt). On September 25, 2020, we completed the Offering of 250,000 shares of our common stock, $0.0001 par value per share,
at an offering price of $60.00 per share (total net proceeds of approximately $12.8 million after underwriting discounts, commissions,
and other offering costs).
On August 2, 2021, we entered into a purchase
agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), under which, subject
to specified terms and conditions, we may sell up to $16.5 million shares of common stock. Our net proceeds under the Purchase Agreement
will depend on the frequency of sales and the number of shares sold to Lincoln Park and the prices at which we sell shares to Lincoln
Park. On August 2, 2021, we sold 63,260 shares of our common stock to Lincoln Park in an initial purchase under the Purchase Agreement
for a total purchase price of $1,500,000. We also issued 12,727 shares of our common stock to Lincoln Park as consideration for its irrevocable
commitment to purchase our common stock under the Purchase Agreement. Total common stock reserved for this Purchase Agreement is 274,014
shares.
On February 16, 2022, we closed on a public offering
of common stock and received approximately $2.51 million of cash proceeds, net of underwriting discounts, commissions, and other offering
costs.
On September 1, 2022, we closed on a public offering
of common stock and concurrent private placement of warrants and received approximately $1.85 million of cash proceeds, net of underwriting
discounts, commissions, and other offering costs.
As of December 31, 2024, our cash and cash equivalent
balance totaled $519,706.
On January 8, 2025, we closed on a public offering
of our common stock and received approximately $3.08 million of cash proceeds, net of underwriting discounts, commissions and other offering
costs.
Going Concern
The accompanying condensed financial statements
have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates the realization
of assets and the satisfaction of liabilities in the normal course of business.
The Company is developing its customer base and
has not completed its efforts to establish a stabilized source of revenue sufficient to cover its expenses. The Company has had a history
of net losses and negative cash flows from operating activities since inception and expects to continue to incur net losses and use cash
in its operations in the foreseeable future.
The assessment of the Company’s ability
to meet its future obligations is inherently judgmental, subjective and susceptible to change. Based on their current forecast, management
believes that it may not have sufficient cash and cash equivalents to maintain the Company’s planned operations for the next twelve
months following the issuance of these condensed financial statements.
The Company has considered both quantitative and
qualitative factors that are known or reasonably known as of the date of these condensed financial statements are issued and concluded
that there are conditions present in the aggregate that raise substantial doubt about the Company’s ability to continue as a going
concern. In response to the conditions, management plans include generating cash by completing financing transactions, which may include
offerings of common stock. However, these plans are subject to market conditions, and are not within the Company’s control, and
therefore, cannot be deemed probable. There is no assurance that the Company will be successful in implementing their plans. As a result,
the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue
as a going concern. The condensed financial statements do not include any adjustments relating to the recoverability and classification
of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.
Critical Accounting Policies and Significant Judgments and Estimates
This management’s discussion and analysis
of financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance
with U.S. GAAP. The preparation of these condensed financial statements requires us to make estimates and assumptions that affect the
reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed financial statements,
and the reported amounts of revenue and expenses during the reported period. In accordance with U.S. GAAP, we base our estimates on historical
experience and on various other assumptions we believe to be reasonable under the circumstances. Actual results may differ from these
estimates if conditions differ from our assumptions. While our significant accounting policies are more fully described in Note 2 in the
“Notes to Condensed Financial Statements,” we believe the following accounting policies are critical to the process of making
significant judgments and estimates in preparation of our condensed financial statements.
Cash, Cash Equivalents, including US Treasury
Market Fund
As of December 31, 2024 and June 30, 2024 our
cash and cash equivalents totaled $519,706 and $2,071,016 respectively with the majority invested in a short-term US Treasury Fund returning
approximately 5%. The Fund is invested in US Treasuries with a 7-day liquidity. The decision to allocate funds to the short-term US Treasury
Fund is based on our investment strategy, which prioritizes liquidity and stability while receiving current rate returns. The returns
from the fund for the six months ended December 31, 2024 were 5.6% and in line with our expectations and the broader market trends for
similar investment vehicles. We continuously monitor our investment portfolio, considering market conditions and our liquidity needs,
ensuring alignment with our broader financial strategy and risk tolerance.
Internally-Developed Capitalized Software
We capitalize certain costs related to the development
of software for our customers, primarily consisting of direct labor and third-party vendor costs associated with creating the software.
Software development projects generally include three stages: the preliminary project stage (all costs are expensed as incurred), the
application development stage (certain costs are capitalized and certain costs are expensed as incurred) and the post-implementation/operation
stage (all costs are expensed as incurred). Costs capitalized in the application development stage include costs related to the design
and implementation of the selected software components, software build and configuration infrastructure, and software interfaces. Capitalization
of costs requires judgment in determining when a project has reached the application development stage, the proportion of time spent in
the application development stage, and the period over which we expect to benefit from the use of that software. Once the software is
placed in service, these costs are amortized on the straight-line method over the estimated useful life of the software, which is generally
three years.
The Company capitalized software of $212,600 and
$118,000 and recognized amortization expense of $218,537 and $279,000 for the six months ended December 31, 2024 and 2023, respectively.
Revenue Recognition
We generate substantially all our revenue from
contractual arrangements with our clients to provide a comprehensive platform of tightly integrated technology and technology enabled
services related to product offerings. Revenue related to our licensing arrangements is generally recognized ratably over the contract
term commencing upon platform delivery. Revenue related to licensing arrangements recognized in a given time period will consist of contracts
that went live in the current period or that went live in previous periods and are currently ongoing.
We have recorded accounts receivable of $0 and
$30,060 as of December 31, 2024 and June 30, 2024, respectively. We have set up deferred revenue liabilities at the end of each period
to reflect performance obligations to be performed in future periods for our services delivered over time. Future obligations related
to deferred revenue totaled $15,925 and $0 as of December 31, 2024 and June 30, 2024 respectively.
The majority of our customers are private and
public learning institutions across various domestic regions. For the six months ended December 31, 2024, one customers comprised approximately
94% of total revenue.
Results of Operations
Revenue
We generated revenues of approximately $24,000
for the six months ended December 31, 2024 as compared to $105,000 for the six months ended December 31, 2023.
We have strongly pivoted
to grow our customer base while reducing risk and losses, resulting in a larger client base, a short-term reduction in overall revenue
and a dramatic reduction in cash burn. Larger, cash-upfront deals were struggling to produce sustainable revenue, as administrative barriers
within nonprofits, high price points set by customers, and inability or unwillingness of customers to partner with schools, businesses
and other entities to purchase products hampered growth.
We continue to believe
that AI-powered learning programs, priced affordably, will supplant other academic products in the mid to long term, but have defocused
on securing “change agent” customers, and are now offering our academic platform for use by any community college on a fee-per-course
basis. The incremental cost to Amesite in delivering the system is de minimis, as the system is turnkey, and the technology
stack is robust. We have focused all new development work on delivering AI tools to markets hungry for increased capability that immediately
impacts both their performance and their bottom line. The NurseMagicTM app is the first of these and has already gained
traction with larger entities.
Stock-Based Compensation
We issue four types of stock-based awards under
our stock plans: stock options, restricted stock units, deferred stock units, and stock warrants. All stock-based awards granted to employees,
directors and independent contractors are measured at fair value at each grant date. We rely on the Black-Scholes option pricing model
for estimating the fair value of stock-based awards granted, and expected volatility is based on the historical volatility of the Company’s
stock prices. Stock options generally vest over two years from the grant date and generally have ten-year contractual terms. Restricted
stock units generally have a term of 12 months from the closing date of the agreement. Stock warrants issued have a term of five years.
Information about the assumptions used in the calculation of stock-based compensation expense is set forth in Note 3 in the Notes to Condensed
Financial Statements.
General and Administrative
General and administrative expenses consist primarily
of personnel and personnel-related expenses, including executive management, legal, finance, human resources and other departments that
do not provide direct operational services. General and administrative expenses also include professional fees and other corporate expenses.
General
and administrative expenses for the six months ended December 31, 2024 were approximately $1,438,000 as compared to approximately $882,000
for the six months ended December 31, 2023. The increase is largely attributable to Board stock compensation and increased legal
and professional fees.
Technology and Content Development
Technology and content development expenses consist
primarily of personnel and personnel-related expenses and contracted services associated with the ongoing improvement and maintenance
of our platform as well as hosting and licensing costs. Technology and content expenses also include the amortization of capitalized software
costs.
Technology
and content development expenses for the six months ended December 31, 2024 were approximately $352,000 as compared to approximately $664,000
for the six months ended December 31, 2023. The decrease is principally related to reductions in headcount and associated administrative
costs, reflecting the completion of certain learning programs that are now offered by our customers and require less staffing to maintain
than to build.
Sales and Marketing
Sales and marketing expense consist primarily
of activities to attract customers to our offerings. This includes personnel and personnel-related expenses, various search engine and
social media costs as well as the cost of advertising.
Sales and
marketing expenses for the six months ended December 31, 2024 were approximately $293,000 as compared to approximately $464,000 for the
six months ended December 31, 2023. The decrease is principally related to refinement of sales and marketing processes to those
that focus messaging directly to our key markets and offer improved lead generation. We have seen increases in marketing qualified leads
(MQLs) in both periods, while reducing the overall sales and marketing spends.
Interest Income
For the
six months ended December 31, 2024, interest income approximated $28,500 as compared to interest income of $110,000 for the six months
ended December 31, 2023.
Net Loss
Our net
loss for the six months ended December 31, 2024 was approximately $2,030,000 as compared to a net loss for the six months ended December
31, 2023 of approximately $1,796,000. The loss was about 11% higher during the six months ended December 31, 2024 compared to 2023
as a result of increased Board stock compensation and professional fees, offset by decreases in technology and content development and
sales and marketing.
Capital Expenditures
During the
six months ended December 31, 2024 and 2023, we had capital asset additions of $212,600 and $118,000 in capitalized technology and content
development. We will continue to capitalize significant software development costs, comprised primarily of internal payroll, payroll
related and contractor costs, as we build out and complete our technology platforms.
Nasdaq Deficiency Letter
On November 26, 2024,
the Company received a deficiency letter (the “Nasdaq Letter”) from the Listing Qualifications Department of The Nasdaq Stock
Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires
the Company to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the
“Stockholders’ Equity Requirement”), nor was it in compliance with either of the alternative listing standards, either
a market value of listed securities of at least $35 million or net income of $500,000 from continuing operations in the most recently
completed fiscal year, or in two of the three most recently completed fiscal years.
Pursuant to the Nasdaq
Letter, the Company had 45 calendar days from the date of the Nasdaq Letter to submit a plan to regain compliance. On January 10, 2025,
the Company submitted a plan to regain compliance. In addition, on January 10, 2025, the Company filed a Current Report on Form 8-K reporting
that as a result of the Company’s January 2025 public offering, that it believed that it had regained compliance with the Stockholders’
Equity Requirement. On January 23, 2025, the Company received written notice from Nasdaq that based on the Company’s Form 8-K dated
January 10, 2025, Nasdaq has determined that the Company complies with the Stockholders’ Equity Requirement and that if the Company
fails to evidence compliance upon filing its next periodic report it may be subject to delisting, at which time Nasdaq will provide written
notification to the Company, which the Company may then appeal to a Hearings Panel.
The Company intends to
take all reasonable measures available to maintain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there
can be no assurance that the Company will be successful in maintaining compliance with the Stockholders’ Equity Requirement and
all applicable requirements for continued listing.
Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure
None.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
The Company is not required to provide the information
required by this Item as it is a “smaller reporting company.”
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this Quarterly
Report on Form 10-Q, we carried out an evaluation, under the supervision, and with the participation of, our management, including our
Chief Executive Officer (principal executive officer) and our Chief Financial Officer (principal financial and accounting officer), of
the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) of the Securities
Exchange Act of 1934, as amended (“Exchange Act”). Based on that evaluation, our management concluded that our disclosure
controls and procedures were not effective due to certain identified material weaknesses.
A material weakness is a deficiency, or combination
of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement
of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.
Specifically, our management concluded that we
did not have existing controls and procedures to review and approve journal entries, and that we did not design control(s) procedures
(i) to ensure that stock compensation expense is correctly calculated and recorded for employees, (ii) over the classification of stock-based
compensation, and (iii) to ensure that deferred revenue is only recorded when payment is received in advance of fulfilling performance
obligations.
Remediation Efforts to Address the Material
Weaknesses
With the oversight of senior management and our
audit committee, we are taking the steps below and plan to take additional measures to remediate the underlying causes of the material
weaknesses:
| ● | The Company will take steps
to remediate the material weaknesses through the documentation of processes and controls for transactions that occur in the course of
business, and in the financial statement close, reporting and disclosure processes. |
| ● | The Company will formalize
our process and documentation for monitoring internal control over financial reporting. The documentation will serve as the evidence
to ascertain whether the control activities are present and functioning, and provide a foundation for the Company to communicate internal
control deficiencies in a timely manner to those parties responsible for taking corrective action. |
In addition, under the direction of the audit
committee of the Board of Directors, management will continue to review and make necessary changes to the overall design of the Company’s
internal control environment, as well as to refine policies and procedures to improve the overall effectiveness of internal control over
financial reporting of the Company.
We cannot be assured that the measures we have
taken to date, or plan to implement, will be sufficient to remediate the material weaknesses we have identified or avoid potential future
material weaknesses.
Changes in Internal Controls Over Financial
Reporting
There were no changes in our internal control
over financial reporting that occurred during the period ended December 31, 2024, that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.
PART II - OTHER INFORMATION
Item 1. Legal Proceedings.
None.
Item 1A. Risk Factors.
Our business, financial condition, results of
operations, and cash flows may be impacted by a number of factors, many of which are beyond our control, including those set forth in
our Annual Report on Form 10-K/A, the occurrence of any one of which could have a material adverse effect on our actual results. There
have been no material changes in our risk factors from those previously disclosed in our Annual Report on Form 10-K/A.
If we are unable to comply with the continued listing requirements
of the Nasdaq Capital Market, then our common stock would be delisted from the Nasdaq Capital Market, which would limit investors’
ability to effect transactions in our common stock and subject us to additional trading restrictions.
On November 26, 2024,
the Company received a deficiency letter (the “Nasdaq Letter”) from the Listing Qualifications Department of The Nasdaq Stock
Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires
the Company to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the
“Stockholders’ Equity Requirement”), nor was it in compliance with either of the alternative listing standards, either
a market value of listed securities of at least $35 million or net income of $500,000 from continuing operations in the most recently
completed fiscal year, or in two of the three most recently completed fiscal years.
Pursuant to the Nasdaq
Letter, the Company had 45 calendar days from the date of the Nasdaq Letter to submit a plan to regain compliance. On January 10, 2025,
the Company submitted a plan to regain compliance. In addition, on January 10, 2025, the Company filed a Current Report on Form 8-K reporting
that as a result of the Company’s January 2025 public offering, that it believed that it had regained compliance with the Stockholders’
Equity Requirement. On January 23, 2025, the Company received written notice from Nasdaq that based on the Company’s Form 8-K dated
January 10, 2025, Nasdaq has determined that the Company complies with the Stockholders’ Equity Requirement and that if the Company
fails to evidence compliance upon filing its next periodic report it may be subject to delisting, at which time Nasdaq will provide written
notification to the Company, which the Company may then appeal to a Hearings Panel.
The Company intends to take all reasonable measures available to maintain
compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be no assurance that the Company will be successful
in maintaining compliance with the Stockholders’ Equity Requirement and all applicable requirements for continued listing.
Neither the Nasdaq Letter nor our noncompliance have an immediate effect
on the listing or trading of the our common shares, which will continue to trade on the Nasdaq Capital Market under the symbol “AMST.”
If the Nasdaq Capital Market delists our common stock from trading
on its exchange and we are not able to list our securities on another national securities exchange, we expect the common stock would qualify
to be quoted on an over-the-counter market. If this were to occur, we could face significant material adverse consequences, including:
| ● | a limited availability of market quotations for our securities; |
| ● | reduced liquidity for our securities; |
| ● | substantially impair our ability to raise additional funds; |
| ● | the loss of institutional investor interest and a decreased
ability to issue additional securities or obtain additional financing in the future; |
| ● | a determination that our common stock is a “penny stock,”
which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading
activity in the secondary trading market for our securities; |
| ● | a limited amount of news and analyst coverage; and |
| ● | potential breaches of representations or covenants of our
agreements pursuant to which we made representations or covenants relating to our compliance with applicable listing requirements, which,
regardless of merit, could result in costly litigation, significant liabilities and diversion of our management’s time and attention
and could have a material adverse effect on our financial condition, business and results of operations. |
Our stock price is and may continue to be volatile and you may
not be able to resell our common stock at or above the price you paid.
The market price for our common stock is volatile and may fluctuate
significantly in response to a number of factors, many of which we cannot control, such as quarterly fluctuations in financial results,
the timing and our ability to advance the development of our product candidates or changes in securities analysts’ recommendations
could cause the price of our stock to fluctuate substantially. Each of these factors, among others, could harm your investment in our
common stock and could result in your being unable to resell the shares of our common stock that you purchase at a price equal to or above
the price you paid.
In addition, the stock markets in general have experienced extreme
volatility that has at times been unrelated to the operating performance of the issuer. Between February 4, 2024 and February 4, 2025,
the closing sales price of our common stock reported on the Nasdaq Capital Market ranged between $1.88 and $5.11 per share. These broad
market fluctuations may adversely affect the trading price or liquidity of our common stock. In the past, when the market price of a stock
has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of our
stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our
management would be diverted from the operation of our business.
We have not developed a strong customer base and we have not
generated sustainable revenue since inception. There can be no assurance that we will be able to do so in the future. We will incur significant
losses in launching products and we may not realize sufficient subscriptions or profits in order to sustain our business.
We have not yet developed a strong customer base and we have not generated
sustainable revenue since inception. We are subject to the substantial risk of failure facing businesses seeking to develop and commercialize
new products and technologies. Maintaining and improving our platform will require significant capital. We also incur substantial accounting,
legal and other overhead costs as a public company. If our offerings to customers are unsuccessful, result in insufficient revenue or
result in us not being able to sustain revenue, we will be forced to reduce expenses, which may result in an inability to gain new customers.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
During the quarter ended December 31, 2024, none
of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement”
or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.
Item 6. Exhibits
Exhibit |
|
|
|
Incorporated by Reference |
|
Filed |
Number |
|
Exhibit Description |
|
Form |
|
File No. |
|
Exhibit |
|
Filing Date |
|
Herewith |
|
|
|
|
|
|
|
|
|
|
|
|
|
3.1 |
|
Certificate of Incorporation of the Registrant |
|
10-Q |
|
001-39553 |
|
3.1 |
|
November 16, 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.2 |
|
Bylaws of the Registrant |
|
10-Q |
|
001-39553 |
|
3.2 |
|
November 16, 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.1 |
|
Form of Senior Debt Indenture, between the Company and one or more trustees to be named |
|
S-3/A |
|
001-39553 |
|
4.2 |
|
December 13, 2024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.2 |
|
Form of Subordinated Debt Indenture, between the Company and one or more trustees to be named |
|
S-3/A |
|
001-39553 |
|
4.3 |
|
December 13, 2024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.3 |
|
Form of Underwriters’ Warrant |
|
8-K |
|
001-39553 |
|
4.1 |
|
January 10, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.1 |
|
Berman CFO Agreement |
|
8-K |
|
001-39553 |
|
10.1 |
|
November 26, 2024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.2 |
|
Underwriting Agreement, dated January 7, 2025, by and between the Company and Laidlaw & Company (UK) Ltd., as representative of the several underwriters listed in Schedule I thereto. |
|
8-K |
|
001-39553 |
|
1.1 |
|
January 10, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.1 |
|
Certification of Chief Executive Officer filed pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
|
|
|
|
|
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
31.2 |
|
Certification of Chief Financial Officer filed pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
|
|
|
|
|
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
32.1* |
|
Certification by Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
|
|
|
|
|
|
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
32.2* |
|
Certification by Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
|
|
|
|
|
|
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
101.INS |
|
Inline XBRL Instance Document |
|
|
|
|
|
|
|
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
101.SCH |
|
Inline XBRL Taxonomy Extension Schema Document |
|
|
|
|
|
|
|
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
101.CAL |
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
|
|
|
|
|
|
|
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
101.DEF |
|
Inline XBRL Taxonomy Extension Definition Linkbase Document |
|
|
|
|
|
|
|
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
101.LAB |
|
Inline XBRL Taxonomy Extension Label Linkbase Document |
|
|
|
|
|
|
|
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
101.PRE |
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
|
|
|
|
|
|
|
|
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
104 |
|
Cover Page Interactive Data File - the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2024 is formatted in Inline XBRL |
|
|
|
|
|
|
|
|
|
X |
* | This certification is deemed
not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), or otherwise subject to the liability
of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the
Exchange Act. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
AMESITE INC. |
|
|
|
Date: February 7, 2025 |
By: |
/s/ Ann Marie Sastry |
|
|
Ann Marie Sastry, Ph.D. |
|
|
Chief Executive Officer |
|
|
(Principal Executive Officer) |
Date: February 7, 2025 |
By: |
/s/ Sarah Berman |
|
|
Sarah Berman |
|
|
Chief Financial Officer |
|
|
(Principal Financial Officer) |
|
|
(Principal Accounting Officer) |
-24-
http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember
0001807166
false
2025
Q2
--06-30
0001807166
2024-07-01
2024-12-31
0001807166
2025-02-05
0001807166
2024-12-31
0001807166
2024-06-30
0001807166
2024-10-01
2024-12-31
0001807166
2023-10-01
2023-12-31
0001807166
2023-07-01
2023-12-31
0001807166
us-gaap:CommonStockMember
2023-06-30
0001807166
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0001807166
us-gaap:RetainedEarningsMember
2023-06-30
0001807166
2023-06-30
0001807166
us-gaap:CommonStockMember
2023-07-01
2023-09-30
0001807166
us-gaap:AdditionalPaidInCapitalMember
2023-07-01
2023-09-30
0001807166
us-gaap:RetainedEarningsMember
2023-07-01
2023-09-30
0001807166
2023-07-01
2023-09-30
0001807166
us-gaap:CommonStockMember
2023-09-30
0001807166
us-gaap:AdditionalPaidInCapitalMember
2023-09-30
0001807166
us-gaap:RetainedEarningsMember
2023-09-30
0001807166
2023-09-30
0001807166
us-gaap:CommonStockMember
2023-10-01
2023-12-31
0001807166
us-gaap:AdditionalPaidInCapitalMember
2023-10-01
2023-12-31
0001807166
us-gaap:RetainedEarningsMember
2023-10-01
2023-12-31
0001807166
us-gaap:CommonStockMember
2023-12-31
0001807166
us-gaap:AdditionalPaidInCapitalMember
2023-12-31
0001807166
us-gaap:RetainedEarningsMember
2023-12-31
0001807166
2023-12-31
0001807166
us-gaap:CommonStockMember
2024-06-30
0001807166
us-gaap:AdditionalPaidInCapitalMember
2024-06-30
0001807166
us-gaap:RetainedEarningsMember
2024-06-30
0001807166
us-gaap:CommonStockMember
2024-07-01
2024-09-30
0001807166
us-gaap:AdditionalPaidInCapitalMember
2024-07-01
2024-09-30
0001807166
us-gaap:RetainedEarningsMember
2024-07-01
2024-09-30
0001807166
2024-07-01
2024-09-30
0001807166
us-gaap:CommonStockMember
2024-09-30
0001807166
us-gaap:AdditionalPaidInCapitalMember
2024-09-30
0001807166
us-gaap:RetainedEarningsMember
2024-09-30
0001807166
2024-09-30
0001807166
us-gaap:CommonStockMember
2024-10-01
2024-12-31
0001807166
us-gaap:AdditionalPaidInCapitalMember
2024-10-01
2024-12-31
0001807166
us-gaap:RetainedEarningsMember
2024-10-01
2024-12-31
0001807166
us-gaap:CommonStockMember
2024-12-31
0001807166
us-gaap:AdditionalPaidInCapitalMember
2024-12-31
0001807166
us-gaap:RetainedEarningsMember
2024-12-31
0001807166
amst:TechnologyAndContentDevelopmentMember
2024-07-01
2024-12-31
0001807166
amst:TechnologyAndContentDevelopmentMember
2023-07-01
2023-12-31
0001807166
us-gaap:OtherCustomerMember
2024-07-01
2024-12-31
0001807166
us-gaap:OtherCustomerMember
2023-07-01
2023-12-31
0001807166
amst:CustomerOneMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2024-07-01
2024-12-31
0001807166
us-gaap:OtherCustomerMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2023-07-01
2023-12-31
0001807166
amst:CustomerOneMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2023-07-01
2023-12-31
0001807166
amst:CustomerTwoMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2023-07-01
2023-12-31
0001807166
2024-01-01
2024-06-30
0001807166
us-gaap:SubsequentEventMember
amst:UnderwritersMember
2025-01-07
2025-01-07
0001807166
us-gaap:SubsequentEventMember
2025-01-07
0001807166
us-gaap:SubsequentEventMember
2025-01-07
2025-01-07
0001807166
us-gaap:SubsequentEventMember
amst:UnderwritersMember
2025-01-08
2025-01-08
0001807166
us-gaap:SubsequentEventMember
2025-01-08
2025-01-08
0001807166
us-gaap:PropertyPlantAndEquipmentMember
2024-07-01
2024-12-31
0001807166
us-gaap:LeaseholdImprovementsMember
2024-12-31
0001807166
us-gaap:FurnitureAndFixturesMember
2024-12-31
0001807166
us-gaap:ComputerEquipmentMember
2024-12-31
0001807166
us-gaap:FiniteLivedIntangibleAssetsMember
2024-07-01
2024-12-31
0001807166
2023-07-01
2024-06-30
0001807166
2021-09-29
2021-09-29
0001807166
amst:CompensationCommitteeMember
2021-09-29
2021-09-29
0001807166
amst:AuditCommitteeMember
2021-09-29
2021-09-29
0001807166
amst:DeferredStockUnitsMember
2024-07-01
2024-12-31
0001807166
amst:CashCompensationMember
2024-07-01
2024-12-31
0001807166
amst:TwothousandeighteenEquityIncentivePlanMember
2024-05-03
0001807166
amst:TwothousandeighteenEquityIncentivePlanMember
2024-05-03
2024-05-03
0001807166
2024-07-11
0001807166
2024-07-01
0001807166
2024-07-01
2024-07-01
0001807166
us-gaap:WarrantMember
2024-07-01
2024-12-31
0001807166
amst:TaxYear2037Member
2024-12-31
0001807166
srt:ScenarioPreviouslyReportedMember
2024-09-30
0001807166
srt:RestatementAdjustmentMember
2024-09-30
0001807166
srt:ScenarioPreviouslyReportedMember
2024-07-01
2024-09-30
0001807166
srt:RestatementAdjustmentMember
2024-07-01
2024-09-30
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
xbrli:pure
In connection with the accompanying
Quarterly Report on Form 10-Q of Amesite Inc. for the period ended December 31, 2024 (the “Report”), the undersigned hereby
certifies in her capacity as Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, to my knowledge and belief, that:
The certification set forth above is being furnished
as an Exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Report or as a separate
disclosure document of Amesite Inc. or the certifying officers.
In connection with the accompanying
Quarterly Report on Form 10-Q of Amesite Inc. for the period ended December 31, 2024 (the “Report”), the undersigned hereby
certifies in her capacity as Principal Financial and Accounting Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, to my knowledge and belief, that:
The certification set forth above is being furnished
as an Exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Report or as a separate
disclosure document of Amesite Inc. or the certifying officers.